

Exhibit 7

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

In the Matter of Registration No. 4,103,919

MARK: REMSIMA

Registered: February 28, 2012

-----X	:	
JANSSEN BIOTECH, INC.,	:	
	:	Cancellation No.
Petitioner,	:	
	:	
- v. -	:	PETITION FOR CANCELLATION
	:	
CELLTRION, INC.	:	
	:	
Registrant.	:	
-----X	:	

Janssen Biotech, Inc. ("Petitioner"), a corporation organized and existing under the laws of the state of Pennsylvania with a principal place of business at 800 Ridgeview Drive, Horsham, Pennsylvania 19044, believes that it will be damaged by the continued registration on the Principal Register of Registration No. 4,103,919 for the mark REMSIMA for "Pharmaceutical preparations for the treatment of autoimmune diseases and autoimmune disorders" in International Class 5 owned by Celltrion, Inc. ("Registrant"), and hereby petitions to cancel the same pursuant to Section 14(3) of the Lanham Act, 15 U.S.C. § 1064(3). As grounds for this petition for cancellation, Petitioner, by its attorneys, Fross Zelnick Lehrman & Zissu, P.C., alleges as follows:

1. Petitioner, a biotechnology company, is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Petitioner's business consists of pursuing innovative solutions in the therapeutic areas of immunology, oncology and nephrology. Since its founding more than thirty years ago, Petitioner has developed numerous successful and innovative treatments to improve the health of individuals with serious disease.

2. One of Petitioner's most successful products currently being offered is a drug sold under the mark REMICADE. For fourteen years, REMICADE has been among the most prescribed medications to help those patients suffering from rheumatoid arthritis and other inflammatory diseases. More than one million people in the US alone use REMICADE to help control and alleviate their symptoms.

3. The REMICADE mark has been used in the U.S. by Petitioner or its predecessors continuously for fourteen years in connection with a medication for the treatment of autoimmune diseases and disorders. Today, the REMICADE brand is recognized nationwide as designating pharmaceutical products exclusively from Petitioner. The REMICADE mark is known among doctors and patients throughout the United States and is a trusted mark that is associated exclusively with Petitioner.

4. Over the last fourteen years, Petitioner has spent millions of dollars in educating consumers and the medical community about the benefits of REMICADE and has spent extensive time, energy and resources in connection with research relating to the use of REMICADE and outreach efforts. Since its launch sales of REMICADE in the US alone are in the hundreds of millions of dollars.

5. Petitioner is the owner of U.S. Trademark Registration No. 2,897,697 for the mark REMICADE and design for "pharmaceutical preparations for the treatment of autoimmune diseases and autoimmune disorders" which registration issued October 26, 2004 based on a constructive priority date of March 29, 2002; and U.S. Trademark Registration No. 2,336,754 for REMICADE for "pharmaceutical compositions for treatment of autoimmune diseases and disorders" which registration issued on March 28, 2000 based on constructive priority dating to July 9, 1998. Printouts from the electronic database records of the United States Patent and

Trademark Office showing the current status and title of Petitioner's registrations for the REMICADE mark are attached hereto as Exhibit A and are made of record and constitute evidence in this proceeding.

6. Petitioner's two registrations for the REMICADE mark are valid, subsisting and in full force and effect and serve as evidence of Petitioner's exclusive right to use the mark in connection with the goods identified in the registrations as provided by Section 33(b) of the Lanham Act, 15 U.S.C. § 1115(b). Further, both Petitioner's registrations have become incontestable under Section 15 of the Lanham Act, 15 U.S.C. § 1065, and serve as conclusive evidence of Petitioner's exclusive right to use the REMICADE mark for the listed goods.

7. By virtue of Petitioner's activities under its mark, the REMICADE mark has become instantly recognizable to the public as exclusively denoting Petitioner and its goods and services. As a result of Petitioner's substantial effort and investment on behalf of its brand, the goodwill inherent in the REMICADE mark is an enormously valuable asset of Petitioner.

8. On information and belief, Celltrion, Inc. is a Republic of Korea corporation, with its principal place of business at 13-6, Songdo-dong Yeonsu-gu Incheon 406-840, Republic of Korea.

9. On or about July 27, 2011, Registrant filed Application Serial No. 79/103,135 to register the mark REMSIMA for "Pharmaceutical preparations for the treatment of autoimmune diseases and autoimmune disorders" in International Class 5. In connection with its application for REMSIMA, Registrant claimed a priority date of January 31, 2011, pursuant to Section 66(a) of the Lanham Act.

10. On information and belief, Registrant intends to sell, advertise and promote its REMSIMA product as a biosimilar of and as a substitute for Petitioner's REMICADE product.

11. On information and belief, Registrant intends to use the REMSIMA mark on

essentially identical goods that Petitioner provides under REMICADE, used for the same purpose and directed to, promoted to and sold to the identical consumers through identical trade channels.

12. Registrant's claimed priority date for the REMSIMA mark is more than a decade after Petitioner's date of first use of its REMICADE mark and a decade after the REMICADE mark was first registered in the U.S. Patent and Trademark Office.

13. As a matter of law, at the time Registrant applied for its mark, Registrant was on constructive notice of Petitioner's rights in the REMICADE mark based on Petitioner's federal trademark registrations for the same. Further, given that Registrant intends to market its product as a biosimilar of REMICADE, Registrant clearly was on actual notice of Petitioner's prior rights in and to the REMICADE mark as of its filing date, if not earlier.

14. In an attempt to trade on the reputation of Petitioner's goods and to assist in the sale of its product as a substitute for REMICADE, Registrant, on information and belief, intentionally adopted a name designed to be similar to and call to mind Petitioner's product name.

15. On information and belief, Registrant's REMSIMA mark was adopted because it is similar in appearance and sound to Petitioner's mark and immediately conjures up Petitioner's mark.

16. Registrant's REMSIMA mark has the identical prefix "REM" as Petitioner's mark, has the same number of syllables and letters as REMICADE and has the same overall appearance, sound and commercial impression as Petitioner's mark.

17. The continued registration of Registrant's REMSIMA mark is inconsistent with Petitioner's long established rights in the REMICADE trademark as well as inconsistent with Petitioner's statutory grant of exclusivity of use of its registered mark and would harm, damage

or destroy Petitioner's investment and goodwill in its mark.

**CLAIM FOR RELIEF FOR LIKELIHOOD OF CONFUSION
UNDER 15 U.S.C. § 1052(d)**

18. Petitioner repeats and re-alleges each and every allegation contained in paragraphs 1 through 17 above as if fully set forth herein.

19. Petitioner's REMICADE mark is exclusively associated with Petitioner and has been used continuously by Petitioner since a date years prior to any date on which Registrant can rely.

20. Registrant's REMSIMA mark incorporates substantial portions and is substantially similar to Petitioner's registered and prior used REMICADE mark and has a similar sound, meaning, appearance and commercial impression to Petitioner's mark.

21. Registrant's registration for the mark sought to be cancelled is for goods identical to those identified in Petitioner's REMICADE registrations. As such, Registrant seeks to use the REMSIMA mark in connection with goods made available to those who use or are familiar with Petitioner's products offered under the REMICADE mark.

22. By virtue of Petitioner's longstanding use of the REMICADE mark and the goodwill associated with the mark, the continued registration by Registrant of the REMSIMA mark is likely to cause confusion or to cause mistake or to deceive the public into mistakenly believing that Registrant's goods offered under the REMSIMA mark originate from, come from or are otherwise associated with Petitioner, or that Registrant's goods are endorsed, licensed, or sponsored by or in some way connected with Petitioner, in violation of Section 2(d) of the Lanham Act, 15 U.S.C. §1052(d).

23. By reason of the foregoing, Petitioner is likely to be harmed by continued registration of the mark REMSIMA shown in Registration No. 4,103,919.

WHEREFORE, Petitioner respectfully requests that this petition for cancellation be sustained and that U.S. Registration No. 4,103,919 be cancelled. The Trademark Trial and Appeal Board is hereby authorized to charge the petition filing fee of \$300 to cancel the registration in Class 5 to Petitioner's counsel's deposit Account Number 30426424.

Dated: New York, New York
April 15, 2014

FROSS ZELNICK LEHRMAN & ZISSU, P.C.

By: 

Barbara A. Solomon

Leo Kittay

866 United Nations Plaza

New York, New York 10017

(212) 813-5900

Attorneys for Petitioner Janssen Biotech, Inc.


CERTIFICATE OF SERVICE

I hereby certify that I have caused a copy of the foregoing Petition for Cancellation to be sent by prepaid overnight courier (Fedex) this 15th day of April, 2014 to the owner of record of the Registration (the USPTO records reflecting no domestic representative of record) that is the subject of the foregoing Petition to Cancel at the correspondence address of record identified in the records of the USPTO:

CELLTRION, INC.
13-6, Songdo-dong
Yeonsu-gu Inchen 406-840
REPUBLIC OF KOREA

with a courtesy copy mailed to the identified correspondent of record:

Sang Jeong An
First & Forever, 7F, Tower A
Advanced Institute
Suwon-si. Gyeonggi-do 443-270
Republic of Korea



Barbara A. Solomon

EXHIBIT A

Int. Cl.: 5

Prior U.S. Cls.: 6, 18, 44, 46, 51, and 52

United States Patent and Trademark Office

Reg. No. 2,897,697

Registered Oct. 26, 2004

**TRADEMARK
PRINCIPAL REGISTER**



Remicade

CENTOCOR, INC. (PENNSYLVANIA CORPORATION)
200 GREAT VALLEY PARKWAY
MALVERN, PA 19355

OWNER OF U.S. REG. NO. 2,336,754.

FOR: PHARMACEUTICAL PREPARATIONS FOR
THE TREATMENT OF AUTOIMMUNE DISEASES
AND AUTOIMMUNE DISORDERS, IN CLASS 5
(U.S. CLS. 6, 18, 44, 46, 51 AND 52).

THE STIPPLING IN THE DRAWING IS FOR
SHADING PURPOSES.

SN 76-390,060, FILED 3-29-2002.

FIRST USE 3-1-2004; IN COMMERCE 3-1-2004.

KAREN K. BUSH, EXAMINING ATTORNEY

Generated on: This page was generated by TSDR on 2014-04-15 13:17:42 EDT

Mark: REMICADE



US Serial Number: 76390060 Application Filing Date: Mar. 29, 2002
US Registration Number: 2897697 Registration Date: Oct. 26, 2004
Register: Principal
Mark Type: Trademark
Status: A Sections 8 and 15 combined declaration has been accepted and acknowledged.
Status Date: Oct. 13, 2010
Publication Date: Oct. 15, 2002 Notice of Allowance Date: Jan. 07, 2003

Mark Information

Mark Literal Elements: REMICADE
Standard Character Claim: No
Mark Drawing Type: 3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S)
Lining and Stippling Statement: The stippling in the drawing is for shading purposes.
Design Search Code(s): 01.15.12 - Cyclones; Tornadoes; Whirlpools
26.01.26 - Coils; Spirals; Swirls

Related Properties Information

Claimed Ownership of US 2336754
Registrations:

Goods and Services

Note: The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((...)) identify any goods/services not claimed in a Section 15 affidavit of
- Asterisks "*" identify additional (new) wording in the goods/services.

For: pharmaceutical preparations for the treatment of autoimmune diseases and autoimmune disorders

International Class(es): 005 - Primary Class

U.S Class(es): 006, 018, 044, 046, 051, 052

Class Status: ACTIVE

Basis: 1(a)

First Use: Mar. 01, 2004

Use in Commerce: Mar. 01, 2004

Basis Information (Case Level)

Filed Use: No	Currently Use: Yes	Amended Use: No
Filed ITU: Yes	Currently ITU: No	Amended ITU: No
Filed 44D: No	Currently 44D: No	Amended 44D: No
Filed 44E: No	Currently 44E: No	Amended 44E: No
Filed 66A: No	Currently 66A: No	
Filed No Basis: No	Currently No Basis: No	

Current Owner(s) Information

Owner Name: JANSSEN BIOTECH, INC.
Owner Address: 800 RIDGEVIEW DRIVE
HORSHAM, PENNSYLVANIA 19044
UNITED STATES
Legal Entity Type: CORPORATION State or Country Where Organized: PENNSYLVANIA

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Laurence S. Rickles

Correspondent

Correspondent LAURENCE S RICKLES
Name/Address: JOHNSON AND JOHNSON CORP
1 JOHNSON AND JOHNSON PLZ
NEW BRUNSWICK, NEW JERSEY 08933-0002
UNITED STATES

Phone: (732) 524-2281

Domestic Representative - Not Found

Prosecution History

Date	Description	Proceeding Number
Apr. 11, 2012	AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP	
Oct. 13, 2010	REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.	64591
Oct. 07, 2010	REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED	64591
Oct. 12, 2010	CASE ASSIGNED TO POST REGISTRATION PARALEGAL	64591
Oct. 07, 2010	PAPER RECEIVED	
May 06, 2009	AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP	
Oct. 26, 2004	REGISTERED-PRINCIPAL REGISTER	
Aug. 25, 2004	LAW OFFICE REGISTRATION REVIEW COMPLETED	71373
Aug. 23, 2004	ASSIGNED TO LIE	71373
Aug. 12, 2004	ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED	
Aug. 09, 2004	ASSIGNED TO EXAMINER	67516
Aug. 05, 2004	STATEMENT OF USE PROCESSING COMPLETE	
Jul. 07, 2004	USE AMENDMENT FILED	
Jul. 22, 2004	CASE FILE IN TICRS	
Jul. 07, 2004	PAPER RECEIVED	
Jan. 05, 2004	EXTENSION 2 GRANTED	
Jan. 05, 2004	EXTENSION 2 FILED	
Jan. 05, 2004	TEAS EXTENSION RECEIVED	
Jul. 11, 2003	EXTENSION 1 GRANTED	
Jul. 03, 2003	EXTENSION 1 FILED	
Jul. 07, 2003	TEAS EXTENSION RECEIVED	
Jan. 07, 2003	NOA MAILED - SOU REQUIRED FROM APPLICANT	
Oct. 15, 2002	PUBLISHED FOR OPPOSITION	
Sep. 25, 2002	NOTICE OF PUBLICATION	
Jul. 24, 2002	APPROVED FOR PUB - PRINCIPAL REGISTER	
Jul. 17, 2002	EXAMINER'S AMENDMENT MAILED	
Jul. 09, 2002	ASSIGNED TO EXAMINER	67516

Maintenance Filings or Post Registration Information

Affidavit of Continued Use: Section 8 - Accepted

Affidavit of Incontestability: Section 15 - Accepted

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: TMEG LAW OFFICE 105

Date in Location: Oct. 13, 2010

Assignment Abstract Of Title Information

Summary

Total Assignments: 2

Registrant: CENTOCOR, INC.

Assignment 1 of 2

Conveyance: CHANGE OF NAME

Reel/Frame: 3978/0441

Pages: 3

Date Recorded: Apr. 29, 2009

Supporting Documents: [assignment-tm-3978-0441.pdf](#)

Assignor

Name: CENTOCOR, INC.

Execution Date: Dec. 29, 2008

Legal Entity Type: CORPORATION

State or Country Where Organized: PENNSYLVANIA

Assignee

Name: CENTOCOR ORTHO BIOTECH INC.

Legal Entity Type: CORPORATION

State or Country Where Organized: PENNSYLVANIA

Address: 800 RIDGEVIEW DRIVE
HORSHAM, PENNSYLVANIA 19044

Correspondent

Correspondent Name: FROSS ZELNICK LEHRMAN & ZISSU, P.C.

Correspondent Address: 866 UNITED NATIONS PLAZA
NEW YORK, NY 10017

Domestic Representative - Not Found

Assignment 2 of 2

Conveyance: CHANGE OF NAME

Reel/Frame: 4748/0177

Pages: 3

Date Recorded: Mar. 29, 2012

Supporting Documents: [assignment-tm-4748-0177.pdf](#)

Assignor

Name: CENTOCOR ORTHO BIOTECH INC.

Execution Date: Jun. 22, 2011

Legal Entity Type: CORPORATION

State or Country Where Organized: PENNSYLVANIA

Assignee

Name: JANSSEN BIOTECH, INC.

Legal Entity Type: CORPORATION

State or Country Where Organized: PENNSYLVANIA

Address: 800 RIDGEVIEW DRIVE
HORSHAM, PENNSYLVANIA 19044

Correspondent

Correspondent Name: MARK D. ENGELMANN

Correspondent Address: FROSS ZELNICK LEHRMAN & ZISSU, P.C.
866 UNITED NATIONS PLAZA
NEW YORK, NY 10017

Domestic Representative - Not Found

Proceedings

Summary

Number of Proceedings: 1

Type of Proceeding: Opposition

Proceeding Number: 91178631

Filing Date: Jul 30, 2007

Status: Terminated

Status Date: Sep 26, 2008

Interlocutory Attorney: LINDA M SKORO

Defendant

Name: Astellas US LLC

Correspondent Address: Rosemary S. Tarlton
Morrison & Foerster LLP
425 Market Street
San Francisco CA , 94105-2482
UNITED STATES

Associated marks

Mark	Application Status	Serial Number	Registration Number
REMISCAN	Abandoned - After Inter-Partes Decision	<u>78890551</u>	
	Plaintiff(s)		

Name: Centocor, Inc.

Correspondent Address: Christen M. English
Drinker Biddle & Reath LLP
1500 K Street, N.W., Ste. 1100
Washington DC , 20005-1209
UNITED STATES

Correspondent e-mail: Christen.English@dbr.com**Associated marks**

Mark	Application Status	Serial Number	Registration Number
REMICADE	Renewed	<u>75516013</u>	<u>2336754</u>
REMICADE	Section 8 and 15 - Accepted and Acknowledged	<u>76390060</u>	<u>2897697</u>

Prosecution History

Entry Number	History Text	Date	Due Date
1	FILED AND FEE	Jul 30, 2007	
2	NOTICE AND TRIAL DATES SENT; ANSWER DUE:	Jul 30, 2007	Sep 08, 2007
3	PENDING, INSTITUTED	Jul 30, 2007	
4	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Aug 02, 2007	
5	SUSPENDED	Aug 02, 2007	
6	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Jan 30, 2008	
7	SUSPENDED	Jan 30, 2008	
8	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Apr 28, 2008	
9	SUSPENDED	Apr 28, 2008	
10	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Jun 26, 2008	
11	SUSPENDED	Jun 26, 2008	
12	WITHDRAWAL OF APPLICATION	Sep 19, 2008	
13	BD'S DECISION: DISMISSED W/O PREJUDICE	Sep 26, 2008	
14	TERMINATED	Sep 26, 2008	

Int. Cl.: 5

Prior U.S. Cls.: 6, 18, 44, 46, 51, and 52

United States Patent and Trademark Office

Reg. No. 2,336,754

Registered Mar. 28, 2000

**TRADEMARK
PRINCIPAL REGISTER**

REMICADE

**CENTOCOR, INC. (PENNSYLVANIA CORPORATION)
200 GREAT VALLEY PARKWAY
MALVERN, PA 19355**

**FIRST USE 9-30-1998; IN COMMERCE
9-30-1998.**

SN 75-516,013, FILED 7-9-1998.

**FOR: PHARMACEUTICAL COMPOSITIONS
FOR TREATMENT OF AUTOIMMUNE DISEASES AND DISORDERS, IN CLASS 5 (U.S. CLS. 6, 18, 44, 46, 51 AND 52).**

RONALD MCMORROW, EXAMINING ATTORNEY

Generated on: This page was generated by TSDR on 2014-04-15 13:16:43 EDT

Mark: REMICADE

REMICADE

US Serial Number: 75516013
US Registration Number: 2336754
Register: Principal
Mark Type: Trademark
Status: The registration has been renewed.
Status Date: Mar. 27, 2010
Publication Date: Jun. 15, 1999
Application Filing Date: Jul. 09, 1998
Registration Date: Mar. 28, 2000
Notice of Allowance Date: Sep. 07, 1999

Mark Information

Mark Literal Elements: REMICADE
Standard Character Claim: No
Mark Drawing Type: 1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S)

Goods and Services

Note: The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [...] indicate deleted goods/services;
- Double parenthesis ((...)) identify any goods/services not claimed in a Section 15 affidavit of
- Asterisks "*" identify additional (new) wording in the goods/services.

For: Pharmaceutical compositions for treatment of autoimmune diseases and disorders

International Class(es): 005 - Primary Class

U.S Class(es): 006, 018, 044, 046, 051, 052

Class Status: ACTIVE

Basis: Basis Not Found

First Use: Sep. 30, 1998

Use in Commerce: Sep. 30, 1998

Basis Information (Case Level)

Filed Use: No	Currently Use: No	Amended Use: No
Filed ITU: Yes	Currently ITU: No	Amended ITU: No
Filed 44D: No	Currently 44D: No	Amended 44D: No
Filed 44E: No	Currently 44E: No	Amended 44E: No
Filed 66A: No	Currently 66A: No	
Filed No Basis: No	Currently No Basis: No	

Current Owner(s) Information

Owner Name: JANSSEN BIOTECH, INC.
Owner Address: 800 RIDGEVIEW DRIVE
HORSHAM, PENNSYLVANIA 19044
UNITED STATES
Legal Entity Type: CORPORATION
State or Country Where Organized: PENNSYLVANIA

Attorney/Correspondence Information

Attorney of Record

Attorney Name: Laurence S. Rickles

Correspondent

Correspondent Name/Address: Laurence S. Rickles
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NEW JERSEY 08933-7001
UNITED STATES

Phone: 732-524-2281

Fax: 732-524-6341

Prosecution History

Date	Description	Proceeding Number
Apr. 11, 2012	AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP	
Mar. 27, 2010	REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)	59136
Mar. 27, 2010	REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED	
Mar. 26, 2010	REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED	59136
Mar. 26, 2010	REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED	59136
Mar. 27, 2010	REVIEW OF CORRESPONDENCE COMPLETE	59136
Mar. 26, 2010	TEAS SECTION 8 & 9 RECEIVED	
May 06, 2009	AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP	
Jul. 06, 2007	CASE FILE IN TICRS	
Jun. 23, 2006	ATTORNEY REVOKED AND/OR APPOINTED	
Jun. 23, 2006	TEAS REVOKE/APPOINT ATTORNEY RECEIVED	
Jun. 07, 2006	REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.	59136
Jun. 01, 2006	ASSIGNED TO PARALEGAL	59136
Feb. 28, 2006	REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED	
Feb. 28, 2006	PAPER RECEIVED	
Mar. 28, 2000	REGISTERED-PRINCIPAL REGISTER	
Dec. 16, 1999	ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED	
Dec. 15, 1999	ASSIGNED TO EXAMINER	73708
Dec. 06, 1999	STATEMENT OF USE PROCESSING COMPLETE	
Nov. 02, 1999	USE AMENDMENT FILED	
Sep. 07, 1999	NOA MAILED - SOU REQUIRED FROM APPLICANT	
Jun. 15, 1999	PUBLISHED FOR OPPOSITION	
May 14, 1999	NOTICE OF PUBLICATION	
Mar. 11, 1999	APPROVED FOR PUB - PRINCIPAL REGISTER	
Mar. 10, 1999	ASSIGNED TO EXAMINER	74666

Maintenance Filings or Post Registration Information

Affidavit of Continued Use: Section 8 - Accepted

Affidavit of Incontestability: Section 15 - Accepted

Renewal Date: Mar. 28, 2010

TM Staff and Location Information

TM Staff Information - None

File Location

Current Location: Not Found

Date in Location: Mar. 27, 2010

Assignment Abstract Of Title Information**Summary**

Total Assignments: 2

Registrant: Centocor, Inc.

Assignment 1 of 2

Conveyance: CHANGE OF NAME

Reel/Frame: 3978/0441

Pages: 3

Date Recorded: Apr. 29, 2009

Supporting Documents: [assignment-tm-3978-0441.pdf](#)

Assignor

Name: CENTOCOR, INC.

Execution Date: Dec. 29, 2008

Legal Entity Type: CORPORATION

State or Country Where Organized: PENNSYLVANIA

Assignee

Name: CENTOCOR ORTHO BIOTECH INC.

Legal Entity Type: CORPORATION

State or Country Where Organized: PENNSYLVANIA

Address: 800 RIDGEVIEW DRIVE
HORSHAM, PENNSYLVANIA 19044

Correspondent

Correspondent Name: FROSS ZELNICK LEHRMAN & ZISSU, P.C.

Correspondent Address: 866 UNITED NATIONS PLAZA
NEW YORK, NY 10017

Domestic Representative - Not Found

Assignment 2 of 2

Conveyance: CHANGE OF NAME

Reel/Frame: 4748/0177

Pages: 3

Date Recorded: Mar. 29, 2012

Supporting Documents: [assignment-tm-4748-0177.pdf](#)

Assignor

Name: CENTOCOR ORTHO BIOTECH INC.

Execution Date: Jun. 22, 2011

Legal Entity Type: CORPORATION

State or Country Where Organized: PENNSYLVANIA

Assignee

Name: JANSSEN BIOTECH, INC.

Legal Entity Type: CORPORATION

State or Country Where Organized: PENNSYLVANIA

Address: 800 RIDGEVIEW DRIVE
HORSHAM, PENNSYLVANIA 19044

Correspondent

Correspondent Name: MARK D. ENGELMANN

Correspondent Address: FROSS ZELNICK LEHRMAN & ZISSU, P.C.
866 UNITED NATIONS PLAZA
NEW YORK, NY 10017

Domestic Representative - Not Found

Proceedings

Summary

Number of Proceedings: 3

Type of Proceeding: Opposition

Proceeding Number: 91186633

Filing Date: Sep 26, 2008

Status: Terminated

Status Date: Jan 11, 2011

Interlocutory Attorney: GEORGE POLOGEORGIS

Defendant

Name: Organish LLC

Correspondent Address: GARY BOURASSA
ORGANISH LLC
150 WEST ST
LAKE GENEVA WI , 53247
UNITED STATES

Correspondent e-mail: gbourassa@organish.com

Associated marks

Mark

Application Status

Serial
Number

Registration
Number

REMACID

Abandoned - After Inter-Partes Decision

77152193

Plaintiff(s)

Name: Johnson & Johnson and Centocor Ortho Biotech Inc.

Correspondent Address: JAYE S CAMPBELL
DRINKER BIDDLE & REATH LLP
1500 K STREET NW, STE 1100
WASHINGTON DC , 20005
UNITED STATES

Correspondent e-mail: weyback@dbr.com , andrea.engel@dbr.com

Associated marks

Mark	Application Status	Serial Number	Registration Number
MILLENNIUM BOARD	Cancelled - Section 8	<u>78305180</u>	<u>2879697</u>
REMICADE	Renewed	<u>75516013</u>	<u>2336754</u>

Prosecution History			
Entry Number	History Text	Date	Due Date
1	FILED AND FEE	Sep 26, 2008	
2	NOTICE AND TRIAL DATES SENT; ANSWER DUE:	Sep 26, 2008	Nov 05, 2008
3	PENDING, INSTITUTED	Sep 26, 2008	
4	ANSWER	Nov 05, 2008	
5	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Jan 05, 2009	
6	SUSPENDED	Jan 05, 2009	
7	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Mar 12, 2009	
8	SUSPENDED	Mar 12, 2009	
9	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Aug 17, 2009	
10	SUSPENDED	Aug 17, 2009	
11	D'S REQUEST TO WITHDRAW AS ATTORNEY	Aug 24, 2009	
12	WITHDRAWAL OF ATTY DENIED; D'S ALLOWED 30 DYS TO FILE MOT THAT COMPLIES	Aug 31, 2009	
13	D'S REQUEST TO WITHDRAW AS ATTORNEY	Sep 14, 2009	
14	D'S REQUEST TO WITHDRAW AS ATTORNEY	Sep 16, 2009	
15	D'S WITHDRAWAL OF ATTY GRANTED; D'S ALLOWED 30 DAYS TO APPT NEW COUNSEL	Sep 17, 2009	
16	D	Sep 17, 2009	
17	SUSPENDED	Nov 03, 2009	
18	NOTICE OF LEGAL REPRESENTATION	Nov 24, 2009	
19	TRIAL DATES RESET	Dec 03, 2009	
20	CORRECTION TO BOARD'S ORDER	Dec 16, 2009	
21	DEF'S NOTICE OF INITIAL DISCLOSURE	Jan 08, 2010	
22	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Jan 11, 2010	
23	SUSPENDED	Jan 11, 2010	
24	Board Order Re: Initial disclosures	Feb 05, 2010	
25	Opposer's Motion to Amend Title of Proceeding	Mar 24, 2010	
26	SUSPENDED	Apr 07, 2010	
27	P'S MOTION TO COMPEL DISCOVERY	Aug 02, 2010	
28	MOTION TO SUSPEND	Aug 02, 2010	
29	SUSPENDED	Aug 04, 2010	
30	P'S MOTION TO COMPEL GRANTED; TRIAL DATES RESET	Oct 06, 2010	
31	P'S MOTION FOR SANCTIONS	Dec 15, 2010	
32	P'S MOT TO SUSP PEND DISP OUTSTNDNG MOT	Dec 15, 2010	
33	SUSPENDED PENDING DISP OF OUTSTNDNG MOT	Dec 15, 2010	
34	BOARD'S DECISION: SUSTAINED	Jan 11, 2011	
35	TERMINATED	Jan 11, 2011	

Type of Proceeding: Opposition

Proceeding Number: 91178631

Filing Date: Jul 30, 2007

Status: Terminated

Status Date: Sep 26, 2008

Interlocutory Attorney: LINDA M SKORO

Defendant

Name: Astellas US LLC

Correspondent Address: Rosemary S. Tarlton

Morrison & Foerster LLP
425 Market Street
San Francisco CA , 94105-2482
UNITED STATES

Associated marks

Mark	Application Status	Serial Number	Registration Number
REMISCAN	Abandoned - After Inter-Partes Decision	<u>78890551</u>	

Plaintiff(s)

Name: Centocor, Inc.

Correspondent Address: Christen M. English
Drinker Biddle & Reath LLP
1500 K Street, N.W., Ste. 1100
Washington DC , 20005-1209
UNITED STATES

Correspondent e-mail: Christen.English@dbi.com

Associated marks

Mark	Application Status	Serial Number	Registration Number
REMICADE	Renewed	<u>75516013</u>	<u>2336754</u>
REMICADE	Section 8 and 15 - Accepted and Acknowledged	<u>76390060</u>	<u>2897697</u>

Prosecution History

Entry Number	History Text	Date	Due Date
1	FILED AND FEE	Jul 30, 2007	
2	NOTICE AND TRIAL DATES SENT; ANSWER DUE:	Jul 30, 2007	Sep 08, 2007
3	PENDING, INSTITUTED	Jul 30, 2007	
4	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Aug 02, 2007	
5	SUSPENDED	Aug 02, 2007	
6	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Jan 30, 2008	
7	SUSPENDED	Jan 30, 2008	
8	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Apr 28, 2008	
9	SUSPENDED	Apr 28, 2008	
10	STIP TO SUSPEND PEND SETTLEMENT NEGOTNS	Jun 26, 2008	
11	SUSPENDED	Jun 26, 2008	
12	WITHDRAWAL OF APPLICATION	Sep 19, 2008	
13	BD'S DECISION: DISMISSED W/O PREJUDICE	Sep 26, 2008	
14	TERMINATED	Sep 26, 2008	

Type of Proceeding: Opposition

Proceeding Number: 91125166

Filing Date: Feb 02, 2002

Status: Terminated

Status Date: Feb 20, 2002

Interlocutory Attorney: CHERYL S GOODMAN

Defendant

Name: CELLTECH THERAPEUTICS LIMITED

Correspondent Address: B. PARKER LIVINGSTON, JR.
BURNS, DOANE, SWECKER & MATHIS, LLP.
POST OFFICE BOX 1404
ALEXANDRIA VA , 22313-1404
UNITED STATES

Associated marks

Mark	Application Status	Serial Number	Registration Number
HUMICADE	Abandoned - After Inter-Partes Decision	<u>76033946</u>	

Plaintiff(s)

Name: CENTOCOR, INC.

Correspondent Address: NORM D. ST. LANDAU
DRINKER, BIDDLE & REATH LLP
1500 K. STREET, N.W. SUITE 1100
WASHINGTON DC , 20005

UNITED STATES

Associated marks

Mark	Application Status	Serial Number	Registration Number
REMICADE	Renewed	<u>75516013</u>	<u>2336754</u>

Prosecution History

Entry Number	History Text	Date	Due Date
1	FILED AND FEE	Feb 02, 2002	
2	NOTICE SENT ANSWER DUE; 3-27-02	Feb 20, 2002	
3	PENDING, INSTITUTED	Feb 20, 2002	
4	DEF'S RETURNED MAIL	Mar 07, 2002	
5	#2 REMAILED; ANSWER DUE 5-7-02; TRIAL DATES RESET	Mar 28, 2002	
6	DEF'S MOT TO EXT.	May 03, 2002	
7	DEF'S MOT TO EXT	Jun 05, 2002	
8	ANSWER	Jul 08, 2002	
9	DEF'S MOT TO EXT W/CON	Aug 28, 2002	
10	PL'S MTN TO EXT W/CON	Oct 17, 2002	
11	PL'S MTN TO EXT. TIME TO RESPOND TO DEF'S DISC.	Nov 25, 2002	
12	MOTION TO EXT APPROVED	Jan 28, 2003	
13	P'S MOT FOR EXTEN. OF TIME W/ CONSENT	Dec 20, 2002	
14	PL'S MOTION TO EXT APPROVED	Mar 20, 2003	
15	PL'S MOT. FOR SANCTION	Jan 22, 2003	
16	BD'S ORDER;PLS REQ. FOR SANCTION IS DENIED;	May 14, 2003	
17	PL'S MOT TO REOPEN TEST. PD	May 29, 2003	
18	PL'S MOT TO SUSPEND	May 29, 2003	
19	PL'S MOT TO SUSPEND/EXT DATES IS GRANTED AS CONCEDED;TD ARE RESET	Jul 25, 2003	
20	DEPOSITION OF FRANK CLOSURDO	Oct 08, 2003	
21	PLAINTIFF'S NOTICE OF RELIANCE	Sep 08, 2003	
22	NOTICE OF RELIANCE	Sep 08, 2003	
23	PLAINTIFF'S NOTICE OF RELIANCE	Sep 08, 2003	
24	PLS MOT FOR ENTRY OF PROTECTIVE ORDER	Oct 02, 2003	
25	BOARD'S ORDER DATES RESET	Jan 13, 2004	
26	BOARD'S ORDER JANUARY ORDER IS VACATED TRIAL DATES REMAIN AS SET	Feb 02, 2004	
27	P'S BRIEF	Feb 19, 2004	
28	SUBMITTED ON BRIEF	Sep 14, 2004	
29	CONFIDENTIAL - PL'S BRIEF	Nov 29, 2004	
30	BRIEF ON MERITS FOR PLAINTIFF	Nov 29, 2004	
31	BOARD'S DECISION: SUSTAINED	Dec 13, 2004	
32	FILINGS	Dec 17, 2004	
33	CONFIDENTIAL - TRANSCRIPT PAGES W/EXHS 3 AND 4	Jan 07, 2005	
34	P's Trial Br	Nov 29, 2004	
35	TERMINATED	May 27, 2005	